
The crux of the transgender-women-in-sport debate is not whether testosterone suppression changes physiology—it does—but whether the residual, measurable differences that often remain translate into sport-relevant performance advantages large enough to justify exclusionary rules; the high-quality evidence is mixed, and the policy question ultimately turns on what threshold of residual advantage a sport is willing to tolerate.
The Short Version
- The literature shows consistent physiological change with testosterone suppression, but disagreement over how much advantage persists and whether it matters competitively.
- Some systematic reviews emphasize no consistent, sport-wide performance advantage after suppression; others highlight modest declines that leave residual differences.
- A frequently cited military-fitness cohort found transgender women’s run times improved relative to cisgender women even after two years on hormones, though the gap narrowed over time.
- The true battleground is evidence thresholds: performance outcomes in specific events versus physiological markers and risk tolerance for unfairness in female categories.
What the science can and cannot currently answer
Two kinds of evidence dominate this field. First are longitudinal studies and systematic reviews tracking how gender-affirming hormone therapy alters hemoglobin, lean mass, muscle cross-sectional area, and strength. These consistently report reductions after testosterone suppression; in several syntheses, absolute values in transgender women remain above cisgender-women averages even after prolonged therapy, though the magnitude varies by study design and follow-up length. Second are performance-proximate studies—cohorts where timed runs, strength tests, or sport-like tasks are measured before and after suppression. Here, findings are sparse and uneven across sports. One of the few widely cited data sets comes from U.S. military fitness testing: transgender women’s running performance slowed after hormone therapy yet remained, on average, faster than cisgender-women comparators two years into suppression; the gap diminished with time but persisted in the 1.5‑mile run window reported publicly.
This split—clear physiological change with nontrivial residuals, plus limited but suggestive performance data—explains why credible analysts reading the same body of work can disagree. Reviews foregrounding absence of consistent, sport-wide outcome advantages conclude the case for categorical exclusion has not been made, especially given observed decrements in strength and hemoglobin and slower post-suppression race times relative to individuals’ pre-transition baselines. Reviews privileging absolute strength and lean-mass comparisons emphasize that typical reductions—on the order of single-digit percentages at 12 months in some cohorts—leave meaningful sex-linked differences intact, with potential implications for power and collision sports.
Why equally qualified experts reach opposite policy judgments
Sports governance is not adjudicated by a single definitive experiment; it is a regulatory craft that balances inclusion, competitive fairness, and administrability. Historically, the International Olympic Committee moved from surgical requirements (Stockholm, 2003) to serum-testosterone thresholds and suppression windows, an implicit acknowledgment that residual advantage is a spectrum management problem rather than a binary identity question. The central methodological divide today is about the reference point and acceptable risk. If the standard is “consistent, sport-wide evidence of superior post-suppression performance,” current data do not meet it in many disciplines, and some syntheses state as much in plain terms. If the standard is “persistence of male-typical physiological traits likely to influence performance,” multiple reviews argue the residuals remain material for certain sports, even as they shrink with time on therapy.
Context matters. Endurance events with high hemoglobin dependence, weight-supported sports leveraging limb length, and collision sports where absolute strength and mass shape injury risk are not interchangeable. Applying a uniform conclusion across all women’s sport—either “no serious evidence of advantage” or “advantage necessarily persists”—overstates what the current record can sustain. The stronger claim is narrower: some domains show plausible, sometimes measured, residual advantages after suppression; in others, evidence is insufficient to infer a durable competitive edge.
The contested datapoints, weighed
Three findings recur in public arguments and deserve careful parsing. First, the military-fitness cohort’s 1.5‑mile run. It is not elite sport, but it is large-sample, standardized, and repeatedly referenced: after two years of hormones, transgender women remained roughly a tenth faster on average than cisgender women in that test, while the gap narrowed over time; the study’s co-author emphasized continued diminishment with longer suppression. That is probative for aerobic capacity and running economy, less so for sports driven by maximal strength or skill acquisition. Second, systematic reviews noting strength and lean-mass decrements that still sit above cisgender-women means even after 36 months—important for power and collision sports but not a direct measure of competitive outcomes. Third, broad reviews that conclude there is no consistent post-suppression performance advantage across sports—accurate at the “consistency across all sport” level, but not dispositive for specific events where performance gaps have been documented.
In short, the aggregate record neither proves an across-the-board, unmitigated advantage nor validates a blanket assurance that meaningful advantages vanish. It shows time-dependent physiological convergence with varying residuals and scattered performance evidence, including at least one well-publicized case of persistent running advantage post-suppression.
Where genuine uncertainty remains—and why it matters
Three research gaps complicate confident generalization. First, follow-up length: many cohorts track one to three years of hormone therapy, yet accrual of training in a new hormonal milieu, tendon remodeling, and body-composition shifts likely extend beyond that horizon. Second, athlete representation: highly trained competitors are underrepresented relative to clinical or military samples, limiting inference to elite performance. Third, confounding control: puberty history, training load, and injury patterns are inconsistently measured, making it hard to apportion what is residual biology versus training adaptation. A recent preprint synthesizing fitness and body-composition data foregrounded exactly these limitations and urged more rigorous, long-term designs before drawing categorical conclusions.
For policy, uncertainty raises a structural question: do you set eligibility to prevent even a modest risk of unfair advantage in the female category—or do you require strong, sport-specific performance evidence before restricting eligibility? Neither choice is value-free; both can be principled. But they are different standards, and conflating them fuels talking past one another.
The sports that have blanket banned trans women their policies are based on the flawed assumption that transgender women retain inherent physical advantages and would therefore dominate women’s competitions.
The research and over 50 years of trans women competing in elite female…
— Kirsti Miller (@KirstiMiller30) November 16, 2026
Practical implications for rulemakers and readers
A durable approach anchors rules in two layers. At the top level, recognize that the women’s category exists to mitigate the performance effects of male puberty; managing residuals from that puberty, not identity per se, is the fairness problem to solve. At the sport level, distinguish event classes by performance determinants. Where aerobic capacity and running economy dominate, the military-fitness result is a caution flag pending better, sport-specific data. Where absolute strength, collision dynamics, or power-to-weight ratios are decisive and safety-relevant, reviews citing persistent strength and lean-mass residuals justify tighter standards while evidence matures. Conversely, in skill-dominant or weight-classified sports, narrower, individualized eligibility may adequately manage residuals without categorical bans.
What the evidence does not support is a sweeping claim that no serious scientific evidence of post-suppression advantage exists. There is serious evidence of both physiological persistence and at least some performance residuals in certain metrics; there is also serious evidence of meaningful decrements and the absence of a uniform, sport-wide advantage signal. Good-faith policy must live with that tension until better, sport-specific longitudinal data resolve it.
Sources:
facebook.com, bjsm.bmj.com, link.springer.com, hal.science, foxnews.com, seattlered.com, cris.brighton.ac.uk










